Mirxes Holding Company Limited
2629.HK
Hong Kong Stock Exchange12.41
HKD
-3.15
- -
ISIN
KYG6152E1052
Return %
Stock
S&P500
1Y
- -
21.04
3Y
- -
71.31
5Y
- -
72.92
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Lihan Zhou
- Full Time Employees
- 350
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2 Tukang Innovation Grove Singapore Singapore 618305
- IPO Date
- May 23, 2025
- Website
- mirxes.com
- Similar Companies
- Business
- Mirxes Holding Company Limited operates in the biotechnology and medical diagnostics sector, focusing on early cancer detection, multi-omics testing, and infectious disease diagnostics, with a strategic emphasis on miRNA-centric platforms and translational research services. Its activities center on developing and commercializing diagnostic solutions and related biotech products, with an expanding footprint in Asia, notably China and Singapore, and ongoing regional collaborations to advance血液-based screening and precision diagnostic offerings. Main Products and Services: - GASTROClear: a blood-based miRNA biomarker panel designed for gastric cancer screening, comprising a defined set of miRNA biomarkers; used as a non-invasive diagnostic aid in high-risk populations and clinical settings. - LungClear (product candidate): a lung cancer screening program leveraging miRNA and multi-omics approaches to identify at-risk individuals; under development and pursuing regulatory and clinical validation processes. - Fortitude COVID-19 RT-qPCR test kits: quantitative PCR based assays for detection of SARS-CoV-2, positioned for use in clinical laboratories and point-of-care settings; includes companion validation and quality control components. - Early Detection and Precision Multi-omics solutions: disease screening and multi-omics candidate discovery services, including miRNA-centric profiling, data analysis, and clinical genomic testing support for biopharmaceutical companies and research institutions. - Multi-omics candidate discovery services: research and development support for biomarker discovery, validation, and translational studies using microRNA and other molecular layers. - Clinical genomic testing services: laboratory-based testing and interpretation services for biomarker-driven projects, including assay development support and data integration for clinical research or diagnostic programs. Latest Major Company Changes: - Strategic joint venture formation for diagnostic manufacturing and commercialization: Mirxes International Holding Limited enters into a joint venture with Xeraya Opportunities Fund PCC Limited to establish MYRNA DIAGNOSTICS SDN. BHD., with ownership 40% by Mirxes International Holding Limited and 60% by Xeraya, broadening manufacturing and regional deployment capabilities in Southeast Asia. This venture expands the company’s regional footprint and accelerates product localization and regulatory pathways. - China regulatory approvals and registrations for core diagnostics: GastroClear receives China NMPA IVD registration certification, enabling commercial distribution and integration into local clinical workflows; company confirms China regulatory clearance for GastroClear as a Class III medical device, reinforcing market access and reimbursement prospects. - Growth through subsidiary activity and corporate reorganization: various HKEX and subsidiary-level updates indicate ongoing organizational developments, including strategic realignments to support product launches, regional expansion, and enhanced manufacturing and distribution capabilities. Additional Context: - Industry and segments: biotechnology and medical diagnostics; Early Detection and Precision Multi-omics; Infectious Diseases diagnostics. - Target markets: healthcare institutions, laboratories, biopharmaceutical companies, and research organizations seeking early detection, multi-omics analysis, and infectious disease testing solutions. - Geographic operations: Asia-focused with activities in China and Singapore, and expansion efforts through regional joint ventures and local regulatory approvals; potential broader coverage in Hong Kong and Southeast Asia. - Founding year and headquarters: founded in 2014; headquartered in Singapore, with corporate structures and subsidiaries in Hong Kong and other regions, reflecting a multi-jurisdictional footprint. - Subsidiaries/parent relationships: Mirxes International Holding Limited acts as a key subsidiary vehicle; the company forms joint ventures to extend manufacturing and regional commercialization; multiple regulatory and corporate developments involve HK-listed entities and cross-border partnerships. Note: This description reflects publicly disclosed developments and product lines as of the most recent regulatory filings and press releases; precise product names, regulatory statuses, and ownership structures are subject to change and should be verified against the latest company disclosures and stock exchange announcements.